GIOPEM
Description
Pemetrexed is among the promising discoveries of the 21st century that changed treatment paradigm for a sub-population of lung cancer patients.Pemetrexed is a multitargeted antifolate that inhibits atleast three folate dependant enzymes involved in DNA synthesis. It is the first choice chemotherapeutic drug for advanced or metastatic non-small cell lung cancer (NSCLC) patients with nonsquamous histology.
Indications:
- For the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin therapy
- For the maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
- For the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer as a single-agent after prior chemotherapy
- For the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery in combination with cisplatin
| Generic Name | Strength | Standard | Type | Packing | Pack Size |
| Pemetrexed | 100 mg | PFS | Vial | ml | |
| Pemetrexed | 500 mg | PFS | Vial | ml |